Impact of Remdesivir on inflammatory and prognostic markers of COVID-19: Findings of an event-monitoring studys
Introduction: Remdesivir is currently approved for treating hospitalised patients with COVID-19. However, it is a priority to monitor its safety and effectiveness in various clinical settings. This study was undertaken to assess the impact of remdesivir on inflammatory and prognostic markers of COVI...
Main Authors: | Shruti Singh, Nishi Sinha, Pallavi Lohani, Neha Agarwal, Pratibha Singh, C M Singh |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2023-01-01
|
Series: | Journal of Family Medicine and Primary Care |
Subjects: | |
Online Access: | http://www.jfmpc.com/article.asp?issn=2249-4863;year=2023;volume=12;issue=12;spage=3135;epage=3141;aulast=Singh |
Similar Items
-
Safety of Remdesivir and Tocilizumab in COVID-19 Treatment
by: Alexandra A. Taube, et al.
Published: (2020-09-01) -
Adverse effects of remdesivir for the treatment of acute COVID-19 in the pediatric population: a retrospective observational study
by: Abigail Schulz, et al.
Published: (2024-02-01) -
Prognostic factors for poor outcomes in patients with severe COVID-19 treated with remdesivir plus dexamethasone in Taiwan
by: Yi-Hsuan Lai, et al.
Published: (2023-12-01) -
Mucocutaneous adverse effects of remdesivir and favipiravir in patients with Covid-19 infection: A systematic review
by: Pradeep Balasubramanian, et al.
Published: (2022-01-01) -
Evaluation of Adverse Drug Events of Remdesivir for the Treatment of COVID-19 in Patients Contacting the 13-Aban Pharmacy Drug and Poison Information Center
by: Amirhosein Ghahremanian, et al.
Published: (2023-09-01)